Peplin has completed its US$6.7 million purchase of private dermatology company Neosil.

The Brisbane biotech issued shares iin common stock in exchange for all equity interests in Neosil, which is developing a topical hair growth product and a broad-spectrum topical anti-microbial agent for acne.

Peplin shareholders have also approved a private placement of stock to raise US$24 million to help fund its Phase III trial of PEP005, a topical gel for sun spots.